JP Patent

JP7738961B2 — ダサチニブの非晶質固体分散体及びその使用

Assigned to ハンダ セラピューティクス リミテッド ライアビリティ カンパニー · Expires 2025-09-16 · 1y expired

What this patent protects

Patent listed against Sprycel.

Drugs covered by this patent

Patent Metadata

Patent number
JP7738961B2
Jurisdiction
JP
Classification
—
Expires
2025-09-16
Drug substance claim
No
Drug product claim
No
Assignee
ハンダ セラピューティクス リミテッド ライアビリティ カンパニー
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.